PENDING FDA GUIDANCE, THIS SITE WILL BE UPDATED. THE FOLLOWING INFORMATION IS A GENERAL OVERVIEW OF OUR FIELD OF WORK.

Tetra is a USA patented and trademarked EDTA catheter lock/flush solution that will be available in a luer-connecting, 12ml, PP syringe, containing 2ml of terminally sterilized EDTA.

No permissions have been granted to any company or individual to sell, market, or use EDTA catheter lock or flush technologies in the USA.

Maintaining patency in a central venous access device is critical to managing quality care for every catheterized patient.

Device occlusions are a source of multiple risks for those patients who rely on a central venous or peripheral access device to provide drugs, nutrition or other life-saving treatments and interventions.

Aseptica has multiple formulations in development for multiple applications.

The need to replace ethanol (off-label) and heparin (FDA Cleared) as Standards-of-care for catheter lock/flushes in select patient populations has driven Aseptica's innovative discovery.

All central venous access devices (IVAD's) require a liquid solution that safely dwells inside the catheter in between 'access' events (a lock) and can be safely flushed into the patient (a flush).

The safety of the EDTA lock/flush developed by Aseptica is likely to revolutionize the future of catheter lock/flush choices.

Aseptica's technology does not control, diagnose, mitigate, monitor or correct a defect of the heart or of the central circulatory system. Aseptica's technology does not achieve it's intended (or Primary) mode of action by pharmocological, immunilogical or metabolic means.

Aseptica's technology does not function as a systemic treatment for any disease. 

Peter Kite, PhD., FIMLS

I am honored to be able to provide an important patient safety technology that will alleviate patient suffering wherever and whenever catheters are used.

April 2, 2020